About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 72722 record(s)
Req # A-2023-000981
The Health Canada indication for Medical Device License (MDL) 69955, specifically, the Contour branded indication, Manufacturer PROLLENIUM MEDICAL TECHNOLOGIES INC.Organization: Health Canada
May 2024
Req # A-2023-001003
The Certified Product Information Document (CPID) submitted for the Treosulfan Abbreviated New Drug Submission (ANDS).Organization: Health Canada
May 2024
Req # A-2023-001005
The Abbreviated New Drug Submission (ANDS) cover letter of the company who submitted the Rupatadine ANDS.Organization: Health Canada
May 2024
Req # A-2023-001006
The Certified Product Information Document (CPID) submitted for the Rupatadine Abbreviated New Drug Submission (ANDS).Organization: Health Canada
May 2024
Req # A-2023-001007
The Abbreviated New Drug Submission (ANDS) cover letter of the company who submitted the Treosulfan ANDS.Organization: Health Canada
May 2024
Req # A-2023-001120
With respect to the Pfizer report entitled, Periodic Safety Update Report, provide: the date it was received; the date when the review was completed and by whom including expertise/specialty; findings including: identified risks of the vaccine;…Organization: Health Canada
May 2024
Req # A-2023-001172
All decisions, including “No Objection” letters or equivalent, with respect to exemptions of “decocainized coca leaf extract” or “decocainized coca leaf extract” or “cocaine-free coca leaf extract” from the Controlled Drugs and Substances Act and…Organization: Health Canada
May 2024
Req # A-2023-001194
All test results relating to the contamination of cantaloupe products, including Malichita or Rudy brand cantaloupes. All emails between Health Canada representatives/employees relating to the contamination of cantaloupe products, including…Organization: Health Canada
May 2024
Req # A-2023-001233
Review Reports from the Bureau of Pharmaceutical Sciences within the Pharmaceutical Drugs Directorate (PDD) for the Marketed drug SOOTHE RESTORE (Drug Identification Number (DIN) 02465302) from company Bausch & Lomb Inc.Organization: Health Canada
May 2024
Req # A-2023-001339
The number of all on-site audits and inventory investigations undertaken by Health Canada with specific reference to changes in tobacco packaging laws, regulations, practices enforceable by Health Canada; the results of these audits; for the…Organization: Health Canada
May 2024